



## **Arvinas to Present at the BMO Prescriptions for Success Healthcare Conference**

June 20, 2019

NEW HAVEN, Conn., June 20, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the BMO Prescriptions for Success Healthcare Conference on Tuesday, June 25 at 2:00 p.m. ET in New York, NY.

A live audio webcast of the presentation will be available [here](#) and at [www.arvinas.com](http://www.arvinas.com) on the Events page. A replay of the webcast will be archived on the Arvinas website for 30 days following the presentation.

### **About Arvinas**

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company's lead program, ARV-110 for the treatment of patients with metastatic castrate-resistant prostate cancer, began a Phase 1 clinical trial in the first quarter of 2019. For more information, see [www.arvinas.com](http://www.arvinas.com).

### **Contacts for Arvinas**

#### **Investors**

Will O'Connor, Stern Investor Relations  
[ir@arvinas.com](mailto:ir@arvinas.com)

#### **Media**

Cory Tromblee, ScientPR  
[pr@arvinas.com](mailto:pr@arvinas.com)



Source: Arvinas Inc.